‘Public Health Crisis’ Warning For Northern Ireland Over Post-Brexit Guidance
Executive Summary
With the likelihood of a UK-EU trade deal still in the balance, the UK life sciences industry has called for clarification from UK and EU regulators regarding the regulatory situation in Northern Ireland from next year.
You may also be interested in...
Life Science Sector Still In The Dark As UK-EU Trade Talks Make Progress
Hope is not lost as the EU sees a "narrow path" to a trade deal with the UK, but the life sciences industry is still facing uncertainty over key issues such as medicines batch testing.
Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.